Company Encyclopedia
View More
name
BOYA BIOLOGY
300294.SZ
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the blood product businesses in China. It offers blood products, such as human coagulation, human prothrombin, human fibrinogen, human albumin, intravenous human immunoglobulin, and rabies immunoglobulin; and non-blood products. The company also provides bone peptide, oxytocin, heparin sodium, and posterior pituitary injection products. In addition, it engages in research, development, production, and sales of anti-infective, diabetes, and cardiovascular drug; and distributes blood products.
1.595 T
300294.SZMarket value -Rank by Market Cap -/-

Financial Score

10/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking7/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE4.29%C
    • Profit Margin16.66%A
    • Gross Margin56.85%B
  • Growth ScoreB
    • Revenue YoY15.06%B
    • Net Profit YoY75.84%A
    • Total Assets YoY6.98%B
    • Net Assets YoY1.19%C
  • Cash ScoreB
    • Cash Flow Margin600.07%C
    • OCF YoY15.06%B
  • Operating ScoreD
    • Turnover0.23D
  • Debt ScoreA
    • Gearing Ratio12.08%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    China Resources Pharmaceutical's subsidiary BOYA BIOLOGY earned 343 million RMB in the first nine months, a decline of 16.8%

    China Resources Pharmaceutical announced that its subsidiary BOYA BIOLOGY had a total operating revenue of 1.474 billion RMB for the nine months ending in September, an increase of 18.4% year-on-year. It recorded a net profit of 343 million RMB, a decline of 16.8%

    AASTOCKS·
    SZ
    300294
    +0.13%
    AASTOCKS·
    SZ
    300294
    +0.13%

    BOYA BIOLOGY: Completed the transfer of 80% equity in Jiangxi Boya Xinhao Pharmaceutical Co., Ltd

    BOYA BIOLOGY has completed the equity transfer with Fuzhou High-tech Zone Financial Investment Group Co., Ltd., transferring 80% of the equity of Jiangxi Boya Xinhao Pharmaceutical Co., Ltd. After this transfer, BOYA BIOLOGY directly holds 10.6869% of the equity of Boya Xinhao, and its wholly-owned subsidiary Jiangxi Boya Pharmaceutical Investment Co., Ltd. holds 9.3131% of the equity. Boya Xinhao will no longer be included in the consolidated financial statements of BOYA BIOLOGY

    Zhitong·
    SZ
    300294
    +0.13%
    Zhitong·
    SZ
    300294
    +0.13%

    BOYA BIOLOGY released its performance for the first half of the year, with a net profit attributable to the parent company of 225 million yuan, a decrease of 28.68%

    According to the Zhitong Finance APP, BOYA BIOLOGY released its semi-annual report for 2025, showing an operating income of 1.008 billion yuan, a year-on-year increase of 12.51%. The net profit attributable to shareholders of the listed company was 225 million yuan, a year-on-year decrease of 28.68%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 166 million yuan, a year-on-year decrease of 36.05%. The basic earnings per share were 0.45 yuan

    Zhitong·
    SZ
    300294
    +0.13%
    Zhitong·
    SZ
    300294
    +0.13%

    BOYA BIOLOGY has established a single plasma collection company in Inner Mongolia

    According to the Qichacha APP, recently, Dalate Banner Boya Single-Collection Plasma Co., Ltd. was established, with Wu Fang as the legal representative. The business scope includes: collection and supply of raw plasma. Qichacha's equity penetration shows that the company is jointly held by BOYA BIOLOGY and others

    Zhitong·
    SZ
    300294
    +0.13%
    Zhitong·
    SZ
    300294
    +0.13%

    CHINARES PHARMA's subsidiary BOYA BIOLOGY's blood plasma collection station has been issued a business license by the Market Supervision Administration of Dalat Qi

    China Resources Pharma's subsidiary, China Resources Boya Biology, has obtained a business license issued by the Market Supervision Administration of Dalad Banner for its single-source plasma station "Dalad Banner Boya Single-Source Plasma Co., Ltd.", allowing for the collection and supply of raw plasma. The plasma station will be constructed in accordance with relevant laws and regulations, and will apply for practice after completion to commence plasma collection work. This move is an important step for China Resources Boya Biology to strengthen its strategic foundation for raw plasma, and is expected to have a positive impact on the overall operations of the group

    AASTOCKS·
    HK
    03320
    -0.87%
    SZ
    300294
    +0.13%
    AASTOCKS·
    HK
    03320
    -0.87%
    SZ
    300294
    +0.13%
    © 2025 Longbridge｜Disclaimer